Voyager Therapeutics Inc. (VYGR)
$3.39
$-0.24
(-6.49%)
As on 05-Jun-2026 13:39EDT
Market cap
$234 Mln
Revenue (TTM)
$36 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
2.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2
-
Face value
--
-
Shares outstanding
60,421,287
10 Years Aggregate
CFO
$-126.50 Mln
EBITDA
$-238.13 Mln
Net Profit
$-229.37 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Voyager Therapeutics (VYGR)
| -13.9 | -12.8 | -18.0 | 2.0 | -33.2 | -4.3 | -12.9 |
|
BSE Sensex
| -12.3 | -3.9 | -6.2 | -8.3 | 5.9 | 7.3 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Voyager Therapeutics (VYGR)
| -30.7 | -32.6 | 38.4 | 125.1 | -62.1 | -48.7 | 48.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Voyager Therapeutics (VYGR)
|
3.4 | 233.8 | 36.5 | -116.6 | -341.5 | -59.3 | -- | 1.4 |
| 73.2 | 10,974.2 | 622.0 | -300.9 | -25.7 | -61.1 | -- | 18.1 | |
| 212.8 | 13,845.5 | 867.5 | 506.6 | -2.8 | -- | 25.5 | 25.6 | |
| 71.1 | 10,421.8 | 105.8 | -829.6 | -715.0 | -- | -- | 60.3 | |
| 52.6 | 12,688.4 | 2,375.5 | 833.4 | 40.8 | 40.7 | 16.7 | 6.5 | |
| 308.9 | 9,110.1 | 417.3 | 225.0 | 42.8 | 18.6 | 41.4 | 7.1 | |
| 490.0 | 11,464.9 | 1,132.5 | -309.4 | -25.5 | -52.9 | -- | 22.4 | |
| 455.6 | 12,769.3 | 2,678.3 | 460.4 | 21.1 | 103.2 | 28.2 | 20.4 | |
| 91.3 | 8,720.6 | 0.0 | -450.1 | -- | -44.6 | -- | 7.2 | |
| 258.8 | 9,756.7 | 0.0 | -326.5 | -- | -37.2 | -- | 7.0 |
Shareholding Pattern
View DetailsAbout Voyager Therapeutics (VYGR)
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of... alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. Read more
-
President, CEO & Director
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
-
President, CEO & Director
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
-
Headquarters
Lexington, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Voyager Therapeutics (VYGR)
What is the current share price of Voyager Therapeutics Inc (VYGR) Today?
The share price of Voyager Therapeutics Inc (VYGR) is $3.39 (NASDAQ) as of 05-Jun-2026 13:39 EDT. Voyager Therapeutics Inc (VYGR) has given a return of -33.21% in the last 3 years.
What is the current PB & PE ratio of Voyager Therapeutics Inc (VYGR)?
Since, TTM earnings of Voyager Therapeutics Inc (VYGR) is negative, P/E ratio is not available.
The P/B ratio of Voyager Therapeutics Inc (VYGR) is 1.37 times as on 29-May-2026, a 69 discount to its peers’ median range of 4.45 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-1.94
|
1.18
|
|
2024
|
-5.06
|
1.10
|
|
2023
|
2.87
|
1.61
|
|
2022
|
-5.13
|
4.03
|
|
2021
|
-1.56
|
1.08
|
What is the 52 Week High and Low of Voyager Therapeutics Inc (VYGR)?
The 52-week high and low of Voyager Therapeutics Inc (VYGR) are Rs 5.55 and Rs 2.83 as of 07-Jun-2026.
What is the market cap of Voyager Therapeutics Inc (VYGR)?
Voyager Therapeutics Inc (VYGR) has a market capitalisation of $ 234 Mln as on 29-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Voyager Therapeutics Inc (VYGR)?
Before investing in Voyager Therapeutics Inc (VYGR), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.